-

American Renal Associates Holdings, Inc. Announces Fourth Quarter 2019 Earnings Release Date and Conference Call

BEVERLY, Mass.--(BUSINESS WIRE)--American Renal Associates Holdings, Inc. (NYSE: ARA), a leading kidney care and dialysis provider focused on partnering with local nephrologists, announced today that it will hold its fourth quarter 2019 earnings conference call on Monday, March 16, 2020 at 5:00 p.m. (Eastern Time). The company plans to release its results after market close the same day.

The conference call can be accessed live over the phone by dialing (877) 407-8029, or for international callers (201) 689-8029. A replay will be available one hour after the call and can be accessed by dialing (877) 660-6853, or for international callers (201) 612-7415. The conference ID for the live call and the replay is 13697054. The replay will be available until March 23, 2020.

Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the company’s website at http://ir.americanrenal.com/. The online replay will be available for a limited time beginning immediately after the call.

About American Renal Associates
American Renal Associates (“ARA”) is a leading provider of outpatient dialysis services in the United States. As of September 30, 2019, ARA operated 244 dialysis clinic locations in 27 states and the District of Columbia serving more than 17,100 patients with end stage renal disease. ARA operates principally through a physician partnership model, in which it partners with approximately 400 local nephrologists to develop, own and operate dialysis clinics. ARA’s Core Values emphasize taking good care of patients, providing physicians with clinical autonomy and operational support, hiring and retaining the best possible staff and providing comprehensive management services. For more information about American Renal Associates, visit www.americanrenal.com.

Contacts

Investor Contact:
Darren Lehrich
Telephone: 978-522-6063; Email: dlehrich@americanrenal.com

American Renal Associates Holdings, Inc.

NYSE:ARA

Release Summary
American Renal Associates Holdings, Inc. Announces Fourth Quarter 2019 Earnings Release Date and Conference Call
Release Versions

Contacts

Investor Contact:
Darren Lehrich
Telephone: 978-522-6063; Email: dlehrich@americanrenal.com

More News From American Renal Associates Holdings, Inc.

American Renal Associates Holdings, Inc. Announces Third Quarter 2020 Results

BEVERLY, Mass.--(BUSINESS WIRE)--American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading kidney care and dialysis provider focused on partnering with local nephrologists, today announced financial and operating results for the third quarter ended September 30, 2020. Certain metrics, including those expressed on an adjusted basis, are Non-GAAP financial measures (See “Use of Non-GAAP Financial Measures” and the reconciliation tables further below). Third Quarter 2020 High...

American Renal Associates Enters Into Definitive Agreement to be Acquired by Nautic Partners

BEVERLY, Mass.--(BUSINESS WIRE)--American Renal Associates Holdings, Inc. (NYSE: ARA) (“ARA” or the “Company”), a leading provider of outpatient dialysis services, today announced that it has entered into a definitive agreement to be acquired by Innovative Renal Care, LLC (“IRC”), an affiliate of Nautic Partners, LLC (“Nautic”), a middle market private equity firm, in an all-cash transaction that values the Company at an aggregate enterprise valuation of approximately $853 million excluding non...

American Renal Associates Holdings, Inc. Announces Settlement of Shareholder Derivative Litigation

BEVERLY, Mass.--(BUSINESS WIRE)--American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading provider of outpatient dialysis services, is pleased to announce that the Company has received preliminary approval of the settlement of a stockholder derivative action brought by Plaintiff Luke Johnson, and pending in the United States District Court for the District of New Jersey (case number No. 19-cv-15812) (the “Johnson Action”). The proposed settlement releases all claims asser...
Back to Newsroom